Gomiliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD23 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
357613-86-6  |
| ChemSpider | none |
| UNII |
8Z13S29R5A  |
| KEGG |
D06463 |
| (what is this?) (verify) | |
Gomiliximab is a monoclonal antibody acting as an immunosuppressive drug for the treatment of allergic asthma. It targets the low affinity IgE receptor (FcεRII or CD23).[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]
This drug was developed by IDEC Pharmaceuticals Corporation.
References
- 1 2 Statement On A Nonproprietary Name Adopted By The Usan Council - Gomiliximab, American Medical Association.
This article is issued from Wikipedia - version of the 10/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.